Egypt is one of highest hepatitis C virus (HCV) endemic areas. Chronic HCV infection has extra-hepatic manifestations, including non-Hodgkin lymphoma (NHL). Diffuse large B-cell lymphoma (DLBCL) is commonly associated with HCV infection. The prognostic value of HCV infection and HCV treatment in patients with DLBCL remains unclear until now.
The aim of our study to evaluate the impact of HCV infection and HCV treatment as independent prognostic factors on the event free survival (EFS) and overall survival (OS) in Egyptian patients with HCV associated DLBCL.
This study included 353 patients with DLBCL were collected retrospective except for 34 patients with HCV who received HCV antiviral therapy were collected prospective. Patients characteristics were collected from the patient records at the time of diagnosis. The status of the patients about HCV infection and HCV treatment were also recorded. Disease progression, relapse, retreatment or deaths were also verified through medical records. EFS and OS were calculated.
EFS and OS significantly decrease in HCV infected and HCV non-treated patients when compared with HCV non-infected and HCV treated patients respectively. HCV infection but not HCV treatment was independently associated with EFS and OS using univariate and multivariate analysis.
Hepatitis C virus infection is an independent prognostic factor for EFS and OS in diffuse large B-cell lymphoma. HCV treatment is associated with higher EFS and OS but can’t be consider as an independent prognostic factor.

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

References

PubMed